Key facts
- Erly Sign’s last known valuation is $2.7M (Jun 2023).
- It has raised $2.1M; the latest was Angel (individual) ($1.8M) in Jan 2025.
- Notable investors include Ashish Kacholia, Anthill Ventures, Amrita Technology Business Incubator, Founders Room Capital, Graycell Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Erly Sign
- ·The full record, as it builds
Funding rounds
No funding rounds for Erly Sign are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Erly Sign
Developer of oral cancer screening platforms designed to enable early detection of oral cancer through non-invasive testing. The company offers a platform that provides a painless and affordable home test kit with risk-level assessments, personalized lifestyle and dietary recommendations, follow-up consultations with nutritionists and doctors, scheduled retesting protocols, and educational resources, enabling individuals and healthcare providers to monitor oral health effectively and support timely medical intervention.
- Sector
- Healthcare
- HQ
- Nagpur, India
- Founded
- 2019
- Employees
- 10
- Website
- erlysign.com/
- Ownership
- Privately Held (backing)
Erly Sign doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Erly Sign shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Erly Sign in its N-PORT filings yet. We sweep new filings monthly.